2. Antibody-drug Conjugate/ADC Related
  3. ADC Linker
  4. 2685873-44-1

2685873-44-1

Tazemetostat de(methyl morpholine)-COOH Chemical Structure

2685873-44-1

Chemical Structure

  • Tazemetostat de(methyl morpholine)-COOH
  • CAS No: 2685873-44-1
    Formula: C30H35N3O5
    Molecular Weight: 517.62
  • IUPAC Name: 3'-(((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)carbamoyl)-5'-(ethyl(tetrahydro-2H-pyran-4-yl)amino)-4'-methyl-[1,1'-biphenyl]-4-carboxylic acid
  • InChIKey: MIEXIPQREXYLRA-UHFFFAOYSA-N
  • SMILES: O=C(C1=CC=C(C2=CC(C(NCC3=C(C)C=C(C)NC3=O)=O)=C(C)C(N(C4CCOCC4)CC)=C2)C=C1)O

Biological Activity: Tazemetostat de(methyl morpholine)-COOH (compound 7) is a ligand for the PROTAC target protein EZH2, which can be used to synthesis of EZH2 degraders (PROTACs). EZH2 degraders have potent cell viability inhibition in diffuse large B-cell lymphoma (DLBCL) and other subtypes of lymphoma[1].

Cat. No. Product Name Purity Description
HY-147091 Tazemetostat de(methyl morpholine)-COOH 98.15% Tazemetostat de(methyl morpholine)-COOH (compound 7) is a ligand for the PROTAC target protein EZH2, which can be used to synthesis of EZH2 degraders (PROTACs). EZH2 degraders have potent cell viability inhibition in diffuse large B-cell lymphoma (DLBCL) and other subtypes of lymphoma.

References

[1]. Tu Y, Sun Y, et al. Design, Synthesis, and Evaluation of VHL-Based EZH2 Degraders to Enhance Therapeutic Activity against Lymphoma. J Med Chem. 2021 Jul 22;64(14):10167-10184. [Content Brief]

Keywords:

Tazemetostat de(methyl morpholine)-COOH